Skip to main content

Table 3 Secondary symptom score endpoints SSS2-4, LSS2-4, and AUC-TSS1-10, ANCOVA-adjusted means, FAS

From: Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial

   

I-C vs. placebo

 

N

Adjusteda mean (SE)

Adjusteda mean (SE) differenceb

95 % CI

p-value*

SSS2–4

     

 I-C

98

1.12 (0.10)

−0.18 (0.15)

(-0.46, 0.11)

0.2310

 Placebo

97

1.30 (0.10)

   

LSS2–4

     

 I-C

98

4.66 (0.22)

−0.44 (0.30)

(-1.04, 0.16)

0.1465

 Placebo

97

5.10 (0.22)

   

AUC-TSS1–10

     

 I-C

98

41.94 (2.19)

0.73 (3.10)

(-5.39, 6.85)

0.8148

 Placebo

97

41.21 (2.20)

   
  1. CI confidence interval, SE standard error
  2. *For ANCOVA-adjusted comparison of placebo with I-C
  3. aThe means were adjusted for baseline SSS, LSS, or TSS
  4. bA negative treatment difference favored I-C
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us